Monocyte-derived interleukin 1 (IL-1) was found to be a potent inducer of platelet-activating factor (PAF) in cultured human vascular endothelial cells (HEC). The product was identified as PAF by its behavior in chromatographic systems, its recovery of biological activity, and its physico-chemical properties and susceptibility to lipases. The response of HEC to IL-i was copcentration-dependent, took more than 2 h to become apparent, and decreased after 18 h of incubafton. Most of tOe PMF produced was cell-associated and only a small amount (about 25% of the total) was released in the culture medium. To study the mechanism of IL-i-induced HEC-PAF production we tested the activity of i-0-alkyl-sn-glycero-3-phospbocholine:acetyl/coenzyme A acetyltransferase in HEC. Acetyltransferase activity measured in IL-i-stimulated HEC lysates showed a three to five times greater maximum velocity, but the same Michaelis constant, as untreated cells.
Introduction
Recent observations suggest that there is a two-way interaction between the immune system and vascular tissue (1) . Products synthesized by lymphomononuclear cells affect several vascular cell functions in vitro and in vivo (2) (3) (4) (5) (6) (7) . More recently, interleukin 1 (IL-l),' a lymphokine produced by stimulated monocytes and macrophages and known to induce differentiation and proliferation of T lymphocytes (8) , was found to interact with human endothelial cells (HEC) in culture, inducing synthesis of thromboplastin (9) and prostacyclin (10) and increasing adhesion of leukocytes on the cells (1 1) .
Platelet-activating factor (PAF; I-o-alkyl-2-acetyl-sn-glycero-3-phosphocholine), a highly potent lipid mediator of inflammation and cell-cell interaction (12) (13) (14) , belongs to a recently IL-1, interleukin 1; L-PC, lyso-phosphatidylcholine; LPS, lipopolysaccharide; PAF, platelet-activating factor, PC, phosphatidylcholine; PCA, tissue procoagulant activity; PG12, prostacyclin; PMNS, polymorphonuclear leukocytes; Rf, retention front on TLC; TLC, thin-layer chromatography. discovered class of autacoids. This compound has potent biological effects on both inflammatory and noninflammatory cells. It causes the activation of platelets, neutrophils, and monocytes (12) (13) (14) and increases Ca2? membrane permeability ofHEC (15) .
In vivo PAF induces bronchoconstriction and vasospasm, and increases vascular permeability and hepatic glycogenolysis ( 12- 14, 16 ). PAF, originally described as a product released from IgE-sensitized rabbit basophils (17), is also released from neutrophils, monocytes, and platelets (12) (13) (14) . More recent experimental evidence indicates that rabbit endothelium and HEC can produce and release PAF during antibody-induced vascular damage or when stimulated with thrombin, angiotensin II, vasopressin, and ionophore A23 187 (18) (19) (20) . The ability of HEC to produce PAF seems relevant in pathophysiological conditions characterized by the interaction between circulating cells and the endothelium (21, 22) . We report here that crude, purified, and recombinant IL-1 promotes PAF generation and release in HEC in culture.
This new activity of IL-I may be an important aspect of the interaction between immunocompetent cells and vascular tissue.
Methods
Materials. The chemicals used and their sources were as follows. PAF
(1-O-octadecyl-2-acetyl-sn-glycero-3-phosphocholine) and lyso-PAF (1-O-octadecyl-sn-glycero-3-phosphocholine) were obtained from Bachem.
Feinkemikalien AG, Bubendorf, Switzerland. [3Hlacetylcoenzyme A (acetyl-CoA; I Ci/mmol, specific activity adjusted by addition of unla- 
1-['4C
]palmitoyl-2-acetyl-sn-glycero-3-phosphocholine was prepared by incubating 200 uCi of dried I-['4Cjpalmitoyl-sn-glycero-3-phosphocholine overnight at room temperature with 2 ml of acetic anhydride and 2 ml of piridine (23 All culture reagents were purchased from GIBCO, Paisley, Scotland.
The plastic flasks and petri dishes came from Falcon Labware, Div. of Becton, Dickinson & Co., Oxnard, CA.
IL-I preparations. Crude IL-1 was obtained from culture supernatants of Percoll-purified (24) monocytes (2 X 106/ml RPMI 1640 medium with 5% fetal bovine serum) stimulated with 25 Mg/ml LPS as described (25) . The supernatants were precipitated with 75% ammonium sulfate and dialyzed against phosphate-buffered saline.
Highly purified IL-1 (Ultrapure IL-1; Genzyme Inc., Boston, MA) was obtained from supernatants of Staphylococcus albus-stimulated monocytes, by absorption on rabbit antibodies coupled to a Sepharose 4B column. After elution from the column, the material, further purified by chromatography on Sephadex G50, gave a homogenous band on sodium dodecyl sulfate-polyacrylamide gel electrophoresis as described (26) .
Purified recombinant murine IL-I (Lot 14430-21) was obtained from Dr. Peter Lomedico at Hoffman-La Roche (27). It was supplied in 5 M guanidine-HCI, and therefore, in some experiments, appropriate controls with guanidine were run with no induction of PAF.
In the crude, purified, and recombinant IL-l preparations, thymocyte co-stimulatory activity was independently evaluated in a co-stimulator assay with C3H/HeJ thymocytes as responding cells and phytohemagglutinin (0.5 Mg/ml) as stimulus (10) . A partially purified IL-l preparation (28) (kind gift from Dr. G. Scala, School of Medicine, University of Naples, Naples, Italy) was assigned a 1000-U/ml value and used as a standard in each assay. Results from triplicate cultures were plotted on a linear regression against the standard preparation and expressed in units per milliliters.
In purified and recombinant IL-l the absence of endotoxin (<0.1 ng/ml ofa solution containing 100 U/ml IL-1) was documented by Limulus assay (Sigma Chemical Co.).
Endothelial cell culture. HEC were cultured, as previously described (29) , in medium 199 supplemented with 20% newborn calf serum and used at the first passage at confluence.
HEC stimulation with IL-I. After removal of the growth medium, the monolayers of intact confluent HEC (1.5-2 X 101 cells in a 4-cm2 culture well) were washed once with 2 ml phosphate buffered saline. Each well was then incubated with 1 ml of serum-free culture medium containing 0.25% bovine serum albumin in the presence or absence of acetyl-CoA and IL-I at the required concentration.
In some experiments aspirin, hirudin, cycloheximide, and polymixin B were added to the cells for the duration of the experiment.
After selected incubation times at 370C, the supernatants were removed from the culture wells, centrifuged for 5 min at room temperature in a microfuge (Beckman Instruments, Inc., Fullerton, CA), and the cells detached with a rubber policeman. Lipids were extracted from the supernatants and the cells according to Bligh and Dyer (30) .
PAFpurification. Lipid-containing, chloroform-rich phases were applied to a silicic acid chromatographic column and eluted with chloroform, acetone-methanol (1:1, vol/vol), and chloroform-methanol (1:4, vol/vol) (31). From the last fraction, PAF was isolated by TLC with chloroform/methanol/H20 (65:35:6, vol/vol) as solvent system (32) . The lipid material, with a retention front (Rf) from 0.15 to 0.22, was extracted (32) and used for biological assay and characterization as described below.
PAFassay. PAFwas detected by aggregation ofwashed rabbit platelets (33) . The amount of PAF was expressed in ng/1.5 X 105 cells and calculated over a calibration curve of synthetic PAF constructed for each test ( 19).
PAF characterization. TLC-purified PAF from each well was resuspended in 0.5 ml isopropanol-n-hexane (1:1, vol/vol). HPLC was performed (34) using a double-pump model 342 M system (Beckman Instruments, Inc., Geneva, Switzerland), equipped with an ultrasphere Si 5 column (Altex Rainin, Berkeley, CA), and connected to a UV-visible detector (204 nm; LKB Produkter AB, Bromma, Sweden). From 2.5 to 10 Ml samples were injected in the column using a model 210 injector (Beckman Instruments, Inc.) with a 20-Ml sample loop. The column was eluted at a flow rate of 2 ml/min using a solvent system of 96% isopropanol-n-hexane (1:1, vol/vol) (solvent A) and 4% H20 (solvent B) with a linear gradient to 8% solvent B over a 15-min period after injection.
Synthetic PAF, PC, and L-PC were used as standard markers. PAF activity of IL-I -stimulated HEC resolved in a unique peak that coeluted with synthetic PAF and PAF derived from A23 187-stimulated HEC (19) between PC and L-PC, showing a retention time of 13-16 min (Fig. 1 ).
The peak resolved by HPLC containing the biologically active material was characterized as PAF by comparison with synthetic PAF and PAF derived from A23 187-stimulated HEC according to the physicochemical (32) and lipase treatments (35) . PAF activity was destroyed after base-catalyzed methanolysis (0.03 N NaOH in methanol for 3 min at 220; 0-1% recovered activity) and treatment with phospholipase A2 (0.03 mg/ml Tris-buffered saline, pH 8, containing 10 mM CaCl2 for 1 h at 37°C; 0-3% recovered activity) indicating the presence of an ester linkage at sn-2.
Substitution via an alkyl ether linkage at sn-l was assessed from the lack of effect of acidic treatment (0.03 N HCI in water for 3 h at 220; 96-100% recovered activity) or lipase AI (0.1 mg/ml borate buffer 0.1 M, pH 6.5, containing 10 mM CaC12, I mM deoxycholate and 0.4% BSA for 20 h, at 220C in stirring; 100% recovered activity). The presence ofa polar head group in sn-3 position was indicated by inactivation with phospholipase C (0.05 mg/ml Tris-buffered saline, pH 8, containing 10 mM CaCl2 for 22 h, at 22°C in stirring; 5-10% recovered activity).
The specificity ofrabbit platelet aggregation induced by PAF derived from IL-l-stimulated HEC was inferred from the inhibitory effect of CV-3988, a PAF antagonist (36) . Preincubation ofwashed rabbit platelets prepared as described (33) with 5-10 MM CV-3988 (5 min at 370C) completely inhibited the biological activity of PAF.
Acetyltransferase activity. HEC stimulated for 6 h in the absence of acetyl-CoA with 10 U/ml IL-l as described above were detached with a rubber policeman and resuspended in I ml of0.25 M sucrose and 1 mM dithiotreitol and then sonicated in an ice bath (Labsonic 1510, B. Braun Melsugen AG, Melsugen, Federal Republic of Germany) at 3 pulses, 10 s, 100 W. Protein was determined by the method of Lowry et al. (37) . The standard reaction mixture (38) 
40 ,g protein in 0.5 ml Tris HCI 0.1 M, pH 6.9, and the reaction was performed at 37°C for 10 min; it was stopped with 3 ml chloroform/ methanol (1:2, vol/vol) and the lipid extracted and chromatographed as above. The layer was scraped in 0.5-mm increments and radioactivity counted in an OCS scintillation liquid.
The radioactivity corresponding to the Rf of synthetic PAF (0.21) was used to measure enzymatic activity. The results were corrected for the radioactivity losses in lipid extraction and TLC purification using L- Results IL-i-induced PAF production by HEC. As shown in Table I , IL-1 at 10 U/ml, after 6 h of incubation with HEC, increased PAF content in the cell extract and in the supernatant. This effect was amplified by the addition ofincreasing concentrations of acetyl-CoA. Acetyl-CoA, in the absence of IL-1, did not in- crease PAF production by HEC. Since acetyl substrate for PAF biosynthesis (39, 40) ampli induced by IL-1, it was included routinely in . erwise specified. The concentration ofacetyl-Cc was 0.1 mM. This concentration has been used to amplify the response of a series of stimuli i without toxic effects (39, 40) . In our hands, tl ofacetyl-CoA in the presence or absence of IL loss of HEC integrity (up to 24 h incubation) release performed as described (10) and trypa (four experiments). (Figs. 3 and 4) ; (b) LPS at 1-CoA acting as a a concentration up to 10 tig/ml had little effect on PAF generified the response ation in the cell extract and supernatant compared with unstimassays unless othulated cells (Fig. 5) ; (c) the lipid A-reactive antibiotic polymixin )A used for assays B (10 ,ug/ml) did not inhibit PAF production induced by crude I by other authors IL-I in the cell extract and in the supernatant (Fig. 5) . Polymixin n other cell types B binds LPS in a stoichiometric manner. Therefore these conhis concentration ditions provide a large excess of this reagent. s diLd not induce It was of interest to elucidate whether human lymphokines as judged by 51Cr other than IL-I interacted with HEC. In three experiments perin blue exclusion formed on three different cell cultures, recombinant interleukin 2 (at 5-10 U/ml), interferon-a and -y, and natural interferoneriment in which A (at 500-1,000 U/ml) had no effect on PAF generation or release times in culture by HEC after 6 h of incubation (data not shown). e PAF was found As shown in Table II , treatment of the cells with cycloheximide caused about 89% inhibition of IL-I induction of cellassociated PAF and 100% inhibition of PAF released in the su-0.5 pernatant.
Since IL-I has been shown to increase PG12 (10) and tissue L -PC procoagulant activity (PCA) (9) in HEC, we tested the effects of , aspirin and hirudin in order to elucidate the possible role of -PG12 or thrombin on IL--induced PAF production. When the cells were treated for the duration ofthe experiment, with aspirin at a concentration of 0.5 mM (which completely blocks PG12 ' synthesis induced by 10 U/ml IL-I (10), or with hirudin (10 U/ ml), no inhibitory effect on IL-I-induced PAF production was apparent in the cell extract or supernatant (Table II) . Table III. of PAF in neutrophils and 25% of PAF in mast cells remained associated to the cells and not released into the medium. In HEC it appears that the amount of PAF released by the cells depends on the type ofstimulus used. Camussi et al. (19) showed that angiotensin II, vasopressin, A23187, and anti-Factor VIII antibody induced significant release of this phospholipid into the medium, while thrombin at the first stimulation was ineffective. Prescott et al. (20) subsequently found that thrombin was indeed able to stimulate PAF synthesis by HEC, but PAF remained completely associated to the cells. These authors also showed that histamine, bradykinin, and adenosine triphosphate stimulated PAF associated to HEC without significant release ofthis substance into the medium. IL-I appears to induce HECassociated PAF synthesis in a manner similar to the latter series of stimuli.
The fact that most of the PAF produced by HEC after IL-I stimulation is not released does not necessarily imply that it is biologically inert. Indeed, Zimmerman et al. (42) showed that thrombin stimulation of HEC increased the adherence of polymorphonuclear leukocytes (PMNS) to these cells. This thrombin effect presented the same time course and concentration depen- dence as thrombin-stimulated PAF production by HEC, and was selectively abolished by PMNS desensitization to PAF. This strongly suggests that PAF synthesized by HEC was appropriately located to interact with adjacent PMNS. Moreover, recent evidence shows that IL-I treatment of HEC markedly increases leukocyte adhesion to these cells (1 1) with a time course very similar to that of IL-I-induced PAF production. It is therefore conceivable that PAF production by HEC after IL-I stimulation could actively contribute to leukocyte activation and adhesion to the cell membrane. The induction of PAF by IL-I required a long interaction with HEC (>2 h) and lasted several hours. In contrast, induction of PAF production in HEC by other stimuli like A23187, (9, 10) . Cycloheximide blocked the effect of IL-I on PGl2, PCA (9, 10), and PAF production. This observation together with the long time-course which characterizes IL-1-induced activities, suggests that the mechanism of action of this lymphokine is protein synthesis-dependent. An increase in l-o-alkyl-sn-glycero-3-phosphocholine: acetylCoA acetyltransferase activity has been shown to be the principal mechanism of PAF generation in different cell types induced by a series ofstimuli (23, 40, 43, 44) . Acetyltransferase was measured in unstimulated and IL-l-stimulated HEC. The study of enzymatic activity in cell extracts showed a three to fivefold increase in Vma, after IL-1 stimulation with no change in the Km values. Similarly, Ninio et al. (23) showed that A23187 stimulation of PAF production in rat peritoneal cells was accompanied by a rapid increase in the Vm. ofthe acetyltransferase with no change in the Km. Other authors have shown that acetyltransferase activity might be stimulated by reversible phosphorylation of the enzyme (45) . At present, further data are required to elucidate the mechanism of action of IL-1 on acetyltransferase and either activation ofthe enzyme or de novo synthesis can be suggested.
The in vivo relevance of the modulation of HEC-PAF production in HEC by IL-l is a matter of speculation. PAF is a very potent inducer of platelet aggregation (46) , leukocyte activation (47) , and neutrophil adhesion to HEC (22) . The range of active PAF concentrations for these cells (22, 46, 47) is very close to those in HEC extracts after IL-l stimulation. In vivo PAF administration has been repeatedly shown to induce a series of cardiovascular effects, platelet aggregation, and leukocyte activation, but the role of HEC-produced PAF in vivo remains to be fully characterized. During IgE-induced systemic anaphylaxis or immune complex-induced neutropenia in the rabbit, PAF release occurs in vivo concomitantly to an acute thrombocytopenia and neutropenia (32, 48, 49) . During these reactions platelets and neutrophils are sequestered in the microvasculature. However, under these experimental conditions, no evidence has been reported of a direct role of endothelial cell-produced PAF in inducing circulating cells to adhere to microvascular endothelial cells. More recently Ito et al. (21) showed that during hyperacute renal allograft rejection in the rabbit, PAF is locally released in the renal microvasculature and platelets and neutrophils aggregate and adhere to the endothelium. This suggests that the endothelium stimulated by transplantation antibodies could be the source of PAF.
Even if more studies are required to investigate its biological relevance, the present demonstration of PAF production by IL-1-stimulated HEC strengthens the concept of a reciprocal interaction between the immune system and vascular cells and further indicates that HEC are able to generate mediators that can locally influence platelets and inflammatory cell functions.
In this study, murine recombinant IL-l from the P388 Dl macrophage line (27) induced synthesis ofPAF in HEC. Recently complimentary (c) DNA clones of human IL-1 have been isolated (50, 51) . These cDNAs encode proteins with IL-l activity on a T cell line or on thymocytes, but are only distantly related (51) . Evidence of heterogeneity of proteins with IL-1 activity also comes from studies on purified natural material (52) . The murine recombinant IL-1 used in this study is closely related to the human cDNA clone designated a, having 62% identical positions (51). As soon as human recombinant IL-ls become available, it will be important to assess their effect on HEC, to determine whether all proteins with IL-I activity affect endothelial and induce the same spectrum of responses in vascular cells.
